GMPPB-Associated Dystroglycanopathy: Emerging Common Variants with Phenotype Correlation.
Braden S Jensen, Tobias Willer, Dimah N Saade...
https://pubmed.ncbi.nlm.nih.gov/26310427/Actively Recruiting
Led by Katherine Mathews · Updated on 2025-07-30
190
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying dystroglycanopathies, a group of muscular dystrophies caused by abnormal glycosylation of alpha-dystroglycan. These inherited disorders involve mutations in more than 20 known genes and cause progressive muscle weakness ranging from congenital muscular dystrophy affecting the brain and eyes to adult-onset limb girdle muscular dystrophy. The study aims to describe early signs and symptoms and collect information needed for future clinical trials. This observational study includes clinical evaluations at the University of Iowa, where participants undergo muscle strength and motor ability testing, lung function tests, quality of life and activity assessments, and a review of their medical history. These evaluations will be repeated approximately once a year. Financial assistance is available to help with travel, and genetic testing support is offered to those diagnosed through muscle or skin biopsy analysis. Participants will be involved in regular assessments to monitor muscle function, including a 10-meter walk test and a 4-stair climb test, repeated annually through the study. Researchers will use this information to improve healthcare recommendations and establish a baseline for future studies and potential treatments. The study allows participation of individuals of any age and sex with varying degrees of muscle weakness but who are otherwise in relatively good health.
CONDITIONS
Clinical Trial Readiness for the Dystroglycanopathies
C
Carrie Stephan, R.N. M.A.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Katherine Mathews
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo clinical evaluations including muscle strength and motor ability testing, lung function tests, quality of life assessments, and review of past medical history.
1 visit (in-person)
Duration - Up to 7 years
Participants return annually for repeated clinical evaluations to monitor disease progression and activity.
Annual visits for up to 7 years
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Braden S Jensen, Tobias Willer, Dimah N Saade...
https://pubmed.ncbi.nlm.nih.gov/26310427/K D Mathews, C M Stephan, K Laubenthal...
https://pubmed.ncbi.nlm.nih.gov/21220724/Brianna N Brun, Tobias Willer, Benjamin W Darbro...
https://pubmed.ncbi.nlm.nih.gov/29759639/Amber M Gedlinske, Carrie M Stephan, Shelley R H Mockler...
https://pubmed.ncbi.nlm.nih.gov/32764098/Chandra L Miller, Lauren N Coffey, Shelley R H Mockler...
https://pubmed.ncbi.nlm.nih.gov/41486779/Eric M Libell, Julia A Richardson, Katie L Lutz...
https://pubmed.ncbi.nlm.nih.gov/32914449/Anna M Reelfs, Carrie M Stephan, Shelley R H Mockler...
https://pubmed.ncbi.nlm.nih.gov/37247532/Cameron D Crockett, Laura A Bertrand, Christopher S Cooper...
https://pubmed.ncbi.nlm.nih.gov/25568299/Paloma Gonzalez-Perez, Cheryl Smith, Wendy L Sebetka...
https://pubmed.ncbi.nlm.nih.gov/32115343/Angela J Lee, Karra A Jones, Russell J Butterfield...
https://pubmed.ncbi.nlm.nih.gov/31041397/Katherine Mathews
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborating Sponsor